These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 31931847)

  • 1. Correction to: DNMT3b/OCT4 expression confers sorafenib resistance and poor prognosis of hepatocellular carcinoma through IL-6/STAT3 regulation.
    Lai SC; Su YT; Chi CC; Kuo YC; Lee KF; Wu YC; Lan PC; Yang MH; Chang TS; Huang YH
    J Exp Clin Cancer Res; 2020 Jan; 39(1):10. PubMed ID: 31931847
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting the PD-L1/DNMT1 axis in acquired resistance to sorafenib in human hepatocellular carcinoma.
    Liu J; Liu Y; Meng L; Liu K; Ji B
    Oncol Rep; 2017 Aug; 38(2):899-907. PubMed ID: 28627705
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Activation of IL6/IGFIR confers poor prognosis of HBV-related hepatocellular carcinoma through induction of OCT4/NANOG expression.
    Chang TS; Wu YC; Chi CC; Su WC; Chang PJ; Lee KF; Tung TH; Wang J; Liu JJ; Tung SY; Kuo LM; Ho HN; Ling TY; Huang YH
    Clin Cancer Res; 2015 Jan; 21(1):201-10. PubMed ID: 25564572
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Author Correction: Macrophages confer resistance to PI3K inhibitor GDC-0941 in breast cancer through the activation of NF-κB signaling.
    Usman MW; Gao J; Zheng T; Rui C; Li T; Bian X; Cheng H; Liu P; Luo F
    Cell Death Dis; 2019 Jun; 10(7):501. PubMed ID: 31235854
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oct4 promotes cancer cell proliferation and migration and leads to poor prognosis associated with the survivin/STAT3 pathway in hepatocellular carcinoma.
    Wang G; Zhou H; Gu Z; Gao Q; Shen G
    Oncol Rep; 2018 Aug; 40(2):979-987. PubMed ID: 29901157
    [TBL] [Abstract][Full Text] [Related]  

  • 6. DNMT1 and DNMT3b silencing sensitizes human hepatoma cells to TRAIL-mediated apoptosis via up-regulation of TRAIL-R2/DR5 and caspase-8.
    Kurita S; Higuchi H; Saito Y; Nakamoto N; Takaishi H; Tada S; Saito H; Gores GJ; Hibi T
    Cancer Sci; 2010 Jun; 101(6):1431-9. PubMed ID: 20398055
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Coexpression of gene Oct4 and Nanog initiates stem cell characteristics in hepatocellular carcinoma and promotes epithelial-mesenchymal transition through activation of Stat3/Snail signaling.
    Yin X; Zhang BH; Zheng SS; Gao DM; Qiu SJ; Wu WZ; Ren ZG
    J Hematol Oncol; 2015 Mar; 8():23. PubMed ID: 25879771
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The anti-obesity drug orlistat promotes sensitivity to TRAIL by two different pathways in hormone-refractory prostate cancer cells.
    Fujiwara J; Sowa Y; Horinaka M; Koyama M; Wakada M; Miki T; Sakai T
    Int J Oncol; 2016 Feb; 48(2):854. PubMed ID: 26648205
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Overexpression of DLX2 is associated with poor prognosis and sorafenib resistance in hepatocellular carcinoma.
    Liu J; Cui X; Qu L; Hua L; Wu M; Shen Z; Lu C; Ni R
    Exp Mol Pathol; 2016 Aug; 101(1):58-65. PubMed ID: 27302463
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interleukin 6 induces cell proliferation of clear cell renal cell carcinoma by suppressing hepaCAM via the STAT3-dependent up-regulation of DNMT1 or DNMT3b.
    Quan Z; He Y; Luo C; Xia Y; Zhao Y; Liu N; Wu X
    Cell Signal; 2017 Apr; 32():48-58. PubMed ID: 28093267
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Secreted GRP78 activates EGFR-SRC-STAT3 signaling and confers the resistance to sorafeinib in HCC cells.
    Li R; Yanjiao G; Wubin H; Yue W; Jianhua H; Huachuan Z; Rongjian S; Zhidong L
    Oncotarget; 2017 Mar; 8(12):19354-19364. PubMed ID: 28423613
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Correction: Activation of IL6/IGFIR Confers Poor Prognosis of HBV-Related Hepatocellular Carcinoma through Induction of OCT4/NANOG Expression.
    Clin Cancer Res; 2016 Dec; 22(24):6303. PubMed ID: 27980027
    [No Abstract]   [Full Text] [Related]  

  • 13. Correction to: Specificity of resistance and geographic patterns of virulence in a vertebrate hostparasite system.
    Piecyk A; Roth O; Kalbe M
    BMC Evol Biol; 2019 May; 19(1):101. PubMed ID: 31084598
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Downregulation of signal transducer and activator of transcription 3 by sorafenib: a novel mechanism for hepatocellular carcinoma therapy.
    Hung MH; Tai WT; Shiau CW; Chen KF
    World J Gastroenterol; 2014 Nov; 20(41):15269-74. PubMed ID: 25386075
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Correction to: Optimisation of a screening platform for determining IL-6 inflammatory signalling in the senescence-associated secretory phenotype (SASP).
    Rolt A; Nair A; Cox LS
    Biogerontology; 2019 Jun; 20(3):373-375. PubMed ID: 30838485
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Signal transducer and activator of transcription 3-mediated CD133 up-regulation contributes to promotion of hepatocellular carcinoma.
    Won C; Kim BH; Yi EH; Choi KJ; Kim EK; Jeong JM; Lee JH; Jang JJ; Yoon JH; Jeong WI; Park IC; Kim TW; Bae SS; Factor VM; Ma S; Thorgeirsson SS; Lee YH; Ye SK
    Hepatology; 2015 Oct; 62(4):1160-73. PubMed ID: 26154152
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Signal transducer and activator of transcription 3 is a major kinase-independent target of sorafenib in hepatocellular carcinoma.
    Tai WT; Cheng AL; Shiau CW; Huang HP; Huang JW; Chen PJ; Chen KF
    J Hepatol; 2011 Nov; 55(5):1041-8. PubMed ID: 21354226
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Correction to: Licochalcone A induces apoptosis through endoplasmic reticulum stress via a phospholipase Cγ1-, Ca
    Choi AY; Choi JH; Hwang KY; Jeong YJ; Choe W; Yoon KS; Ha J; Kim SS; Youn JH; Yeo EJ; Kang I
    Apoptosis; 2019 Feb; 24(1-2):200-203. PubMed ID: 30390185
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sorafenib enhances radiation-induced apoptosis in hepatocellular carcinoma by inhibiting STAT3.
    Huang CY; Lin CS; Tai WT; Hsieh CY; Shiau CW; Cheng AL; Chen KF
    Int J Radiat Oncol Biol Phys; 2013 Jul; 86(3):456-62. PubMed ID: 23474115
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oncofetal HLF transactivates c-Jun to promote hepatocellular carcinoma development and sorafenib resistance.
    Xiang DM; Sun W; Zhou T; Zhang C; Cheng Z; Li SC; Jiang W; Wang R; Fu G; Cui X; Hou G; Jin GZ; Li H; Hou C; Liu H; Wang H; Ding J
    Gut; 2019 Oct; 68(10):1858-1871. PubMed ID: 31118247
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.